Clinical Trial Update: Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 trial update on VX-445/TEZ/IVA (elexacaftor/tezacaftor/ivacaftor) in children aged 6-11 with cystic fibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-445/TEZ/IVA

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2021-10-22